Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Phathom Pharmaceuticals (PHAT) EBT Margin (2022 - 2025)

Phathom Pharmaceuticals (PHAT) has disclosed EBT Margin for 4 consecutive years, with 36.72% as the latest value for Q4 2025.

  • On a quarterly basis, EBT Margin rose 21443.0% to 36.72% in Q4 2025 year-over-year; TTM through Dec 2025 was 126.24%, a 47884.0% increase, with the full-year FY2025 number at 126.24%, up 47884.0% from a year prior.
  • EBT Margin was 36.72% for Q4 2025 at Phathom Pharmaceuticals, up from 60.53% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 1473.65% in Q1 2022 to a low of 11665.1% in Q4 2023.
  • A 4-year average of 1164.87% and a median of 191.51% in 2025 define the central range for EBT Margin.
  • Peak YoY movement for EBT Margin: crashed -1223745bps in 2023, then skyrocketed 1141396bps in 2024.
  • Phathom Pharmaceuticals' EBT Margin stood at 572.35% in 2022, then tumbled by -2138bps to 11665.1% in 2023, then skyrocketed by 98bps to 251.15% in 2024, then soared by 85bps to 36.72% in 2025.
  • Per Business Quant, the three most recent readings for PHAT's EBT Margin are 36.72% (Q4 2025), 60.53% (Q3 2025), and 191.51% (Q2 2025).